cetus corp said european patent office allowed and intends grant company patent for pharmaceutical and veterinary preparations genetically engineered interleukin analog interleuken immune modulating protein currently undergoing clinical trials united states and europe for potential treatment various forms cancer cetus said said allowance first step patent process following allowance patent published for opposition and nine month period begins during which interested parties have opportunity voice any objections patent cetus said reuter 